Oval Medical Technologies recently announced that it moved to a new facility in Cambridge Research Park, U.K.
The new facility offers dedicated GMP labs, enhanced device development, space for an expanded team and room for growth. The Cambridge, U.K.-based company touts the facility as being a one-stop-shop from device design to delivery of a finished commercial product.
“Our autoinjector platforms are creating huge opportunities for pharmaceutical companies to develop new products and to improve established formulations,” CEO Barbara Lead said in a press release. “This move provides the needed space to continue to grow and develop cutting edge technology platforms serving pharmaceutical companies and patients.”
Oval Medical Technologies currently manufactures patient-centric autoinjector platforms that allow pharmaceutical companies to deliver a number of drug formulations subcutaneous and intramuscular injections.
“Our principal aim is to partner our patient-centric autoinjectors with an integrated start to finish solution – one that’s easy for patients and easy for partners. Our expanded new facility makes that objective more achievable,” chief technology officer Matthew Young said.
